Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
    • All Access
      • Learn More
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » New Agent for Treatment of Chagas Disease Disappoints in Clinical Trial
    ABSTRACT & COMMENTARY

    New Agent for Treatment of Chagas Disease Disappoints in Clinical Trial

    March 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    By Dean L. Winslow, MD, FACP, FIDSA

    Professor of Medicine, Division of General Medical Disciplines, Division of Infectious Diseases and Geographic Medicine, Stanford University

    Dr. Winslow reports no financial relationships relevant to this field of study.

    SYNOPSIS: A randomized, controlled trial of E1224 (a ravuconazole prodrug) in different doses and durations was studied in adult patients with chronic indeterminate Chagas disease. Parasite clearance was observed in treated patients, but the response was transient in most patients.

    SOURCE: Torrico F, Fascon J, Ortiz L, et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: A proof-of-concept, randomized, placebo-controlled trial. Lancet Infect Dis 2018 Jan 15: pii: S1473-3099(17)30538-8. [Epub ahead of print].

    A proof-of-concept, double-blind, randomized, Phase II clinical trial was conducted in two outpatient units in Bolivia. During 2011-2012, 560 patients with chronic Chagas disease were screened and 231 were randomized. Patients were randomized 1:1:1:1:1 to oral E1224 high dose/eight weeks, low dose/eight weeks, short dose (four weeks E1224 followed by four weeks of placebo), benznidazole 5 mg/kg for 60 days, and placebo for eight weeks. The primary efficacy endpoint was parasitological clearance as assessed by polymerase chain reaction (PCR), and secondary endpoints included serologic response and changes in biomarkers.

    Parasite clearance was observed with E1224 during treatment administration, but no sustained response was seen with either the low-dose or short-course treatment regimens. Thirteen of 45 (29%) patients treated with high-dose E1224 compared with four of 47 (9%) in the placebo group had sustained responses at 12-month follow up. In contrast, benznidazole had a rapid and sustained effect on parasite clearance, with 37 of 45 (82%) at 12-month follow up as assessed by PCR. Both E1224 and benznidazole were well tolerated, with reversible dose-dependent increase in liver enzymes seen in both E1224- and benznidazole-treated patients, but only six patients in the study (3%) developed treatment-emergent serious adverse events.

    COMMENTARY

    This well-designed, randomized, placebo-controlled, proof-of-concept study demonstrated that this new imidazole prodrug had modest in vivo activity as shown by dose-dependent suppression of parasitemia as assessed by PCR. However, it was disappointing that E1224 did not appear as active as benznidazole.

    This follows fairly shortly after the publication of another disappointing randomized, placebo-controlled trial in which benznidazole, while showing parasitological clearance, had no clinical efficacy in the treatment of patients with different stages of Chagas cardiomyopathy.1 However, the fact that E1224 demonstrated trypanosomal DNA reduction activity in vivo suggests that trials of E1224 in combination with benznidazole or nifurtimox should be conducted.

    REFERENCE

    1. Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. N Engl J Med 2015;373:1295-1306.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Infectious Disease Alert

    View PDF
    Infectious Disease Alert (Vol. 37, No. 6) March 2018
    March 1, 2018

    Table Of Contents

    Prolonged vs. Short Duration Infusion of Beta-lactam Antibiotics: The Verdict Is In

    MRSA Infections May Lead to Prolonged Impairment of Lymphatic Vessel Function

    Mefloquine: Still Effective and Still Safe for Malaria Chemoprophylaxis

    New Agent for Treatment of Chagas Disease Disappoints in Clinical Trial

    Does Adding Rifampin to Standard Therapy Improve Outcomes in Patients With Staphylococcus aureus Bacteremia?

    What Do the Urinary Microbiota and Incontinence Have to Do With Each Other?

    Infectious Disease Alert Updates

    Begin Test

    Buy this Issue/Course

    Clinical Briefs in Primary Care

    Pharmacology Watch

    Financial Disclosure: Infectious Disease Alert’s Editor Stan Deresinski, MD, FACP, FIDSA, Peer Reviewer Patrick Joseph, MD, Updates Author Carol A. Kemper, MD, FACP, Peer Reviewer Kiran Gajurel, MD, Executive Editor Shelly Morrow Mark, Editor Jonathan Springston, and Editorial Group Manager Terrey L. Hatcher report no financial relationships to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events

    Free Email Newsletters

    All Fields Required

    E-Newsletter Options
    • Accreditation Council for Continuing Medical Education
    • American Nurses Credentialing Center
    • American College of Emergency Physician
    • American Board of Internal Medicine: Maintenance of Certification
    • California Board of Registered Nursing
    • Commission for Case Manager Certification
    • American Academy of Pediatrics
    • American Osteopathic Association
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
      • Libraries
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Live Webinars
      • On-Demand Webinars
    • All Access
      • Learn More
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2019 Relias. All rights reserved.

    Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing